Nemolizumab
| Nemolizumab
| |
|---|---|
| Routes of administration | Subcutaneous injection
|
| Metabolism | Proteolytic enzymes
|
| Legal status | Investigational |
| CAS Number | 1476039-58-3
|
| ChemSpider | none |
| KEGG | D11080
|
Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis.[1] It is a monoclonal antibody that blocks the interleukin-31 receptor A.[2] Results of a Phase II clinical trial were published in March 2017.[3]
Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.[4]
References[edit]
- ↑ H. Spreitzer."Neue Wirkstoffe - Nemolizumab".Österreichische Apothekerzeitung.27 March 2017;(7/2017)
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 74".WHO Drug Information.2015;29(3)
- 411.Full text.
- ↑ "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis".New England Journal of Medicine.2017;376(9)
- 826–835.doi:10.1056/NEJMoa1606490.PMID:28249150.
- ↑ , Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma Full text, , Pharmabiz.com, 22 July 2016,
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
